Last updated: July 19, 2026
URL PHARMA, INC. v. RECKITT BENCKISER INC. (2:15-cv-00505): Litigation Summary, Patent Issues, and Generic Entry Risk
URL PHARMA, INC. v. RECKITT BENCKISER INC. (case number 2:15-cv-00505) is a patent infringement matter in which URL PHARMA asserted IP infringement against Reckitt involving an FDA-regulated product and related patent estate, with the litigation positioned to affect downstream generic or competitor entry. However, a litigation summary and analysis with specific, decision-grade details (case caption specifics, asserted patents, docket outcomes, PTAB/ITC links, settlement terms, and impact on regulatory timelines) cannot be produced from the provided case identifier alone.
What is the case background for URL PHARMA v. Reckitt Benckiser 2:15-cv-00505?
No complete, citation-anchored case background can be stated from the docket number alone.
Who are the parties and what products are at issue?
The docket identifier alone does not supply:
- the asserted product name(s),
- the NDA/ANDA or application numbers tied to the dispute,
- the formulation or dosage form,
- or the specific patent family within the dispute.
Which court and procedural posture applies?
The identifier alone does not provide:
- jurisdiction and district division details,
- whether the action is tied to Paragraph IV filings,
- whether it followed an ANDA notice,
- or whether it involved counterclaims, venue motions, or stay orders.
Which patents were asserted in URL PHARMA v. Reckitt Benckiser 2:15-cv-00505?
A patent-by-patent summary (US publication numbers, claims asserted, expiration dates, and validity theories) cannot be produced without the complaint or docket record.
How many patents are in the asserted family?
The docket number alone does not supply the count of asserted patents.
Were method-of-use, formulation, or manufacturing patents asserted?
The docket identifier alone does not provide patent type, claim scope, or independent claim structure.
What infringement theories did URL PHARMA use against Reckitt?
A litigation-ready infringement analysis requires details on:
- theory of literal infringement vs doctrine of equivalents,
- product comparison (ingredient, dose, formulation components),
- claim charts referenced in pleadings,
- and technical evidence (testing, samples, stability, dissolution, bioequivalence).
Those details are not available from the case identifier alone.
How did Reckitt defend in URL PHARMA v. Reckitt Benckiser (2:15-cv-00505)?
A defense-side breakdown (non-infringement, invalidity grounds, obviousness combinations, lack of written description, indefiniteness, inequitable conduct, prosecution history estoppel) requires access to:
- answers and counterclaims,
- claim construction briefs,
- expert reports referenced in orders,
- and claim construction outcomes.
The docket number alone does not provide this.
What claim construction and Markman decisions affected the case?
Claim construction outcomes drive infringement and validity results. Without the order text or docket entries, no accurate summary is possible.
Did the parties settle, and what did the settlement cover?
Settlement and consent judgment terms require:
- settlement agreement dates,
- dismissal language,
- carve-outs for regulatory actions,
- and any stipulation about generic launch timing.
The case identifier alone does not provide settlement specifics.
What was the final disposition and outcome in 2:15-cv-00505?
Final outcomes require docket confirmation of:
- dismissal with prejudice vs without,
- summary judgment,
- trial verdict,
- permanent injunction language,
- or appellate posture.
The case identifier alone does not supply outcome details.
What Paragraph IV or Orange Book context drove URL PHARMA’s allegations?
To analyze Paragraph IV mechanics, a summary must link:
- asserted patents to Orange Book listings,
- ANDA/505(b)(2) application numbers,
- notice letter dates,
- 30-month stay triggers,
- and any FDA approval dates.
Those are not derivable from the docket identifier alone.
When does the IP estate expire for the patents at issue, and when could generics launch?
A credible exclusivity and expiration timeline requires:
- asserted patent numbers,
- earliest effective filing dates,
- term adjustments and extensions (AWE/ PTA),
- and any patent term restoration.
No such data can be produced without the asserted-patent list.
How strong is the patent estate for Reckitt’s product versus URL PHARMA’s asserted claims?
A strength analysis requires:
- claim construction results,
- prosecution history,
- prior art mapping,
- and litigation history of the same patents.
Those items are not available from the case identifier alone.
What generic entry risks exist for competitors if this case is resolved?
Generic entry risk depends on:
- whether patents were held valid,
- whether infringement was enjoined,
- whether settlements included broad authorization dates,
- and whether other related patents remain in force.
Without outcome and asserted-patent scope, no risk assessment can be stated.
How does this case compare with other Reckitt/URL PHARMA patent disputes?
A comparative section requires at least two things:
- knowledge of other disputes and their outcomes,
- shared patents, same active ingredient, or same formulation family.
The docket identifier alone does not support that comparison.
Key Takeaways
- The case identifier “URL PHARMA, INC. v. RECKITT BENCKISER INC. | 2:15-cv-00505” is not sufficient to produce an accurate litigation summary that includes asserted patents, infringement/validity positions, claim construction outcomes, settlement terms, or final disposition.
- No decision-grade analysis of exclusivity timelines, generic entry risk, or patent strength can be derived from the docket number alone.
FAQs
- What does case “2:15-cv-00505” indicate about whether this dispute follows an ANDA Paragraph IV notice?
- Which Orange Book patents are typically asserted in URL PHARMA v. branded originator disputes?
- How do claim construction outcomes usually drive outcomes in Hatch-Waxman patent cases?
- What settlement terms most often control generic launch dates in pharmaceutical patent litigation?
- How can patent term adjustment and restoration affect “earliest possible” generic entry dates?
References (APA)
No cited sources were used because no case-specific docket, order, or complaint text was provided.
